Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)

被引：0
|
作者：
Loriot, Yohann
Matsubara, Nobuaki
Park, Se Hoon
Huddart, Robert A.
Burgess, Earle F.
Houede, Nadine
Banek, Severine
Laguerre, Brigitte
Guadalupi, Valentina
Ku, Ja Hyeon
Triantos, Spyros
Akapame, Sydney
Deprince, Kris
Mukhopadhyay, Sutapa
Siefker-Radtke, Arlene O.
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, INSERM 981, Villejuif, France
[2] Natl Canc Ctr Hosp East, Dept Med Oncol, Chiba, Japan
[3] Sungkyunkwan Univ, Samsung Med Ctr, Gangnam, South Korea
[4] Inst Canc Res, Sect Radiotherapy & Imaging, Sutton, Surrey, England
[5] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[7] CHU Caremeau, Inst Cancerol Gard, Dept Med Oncol, Nimes, France
[8] Goethe Univ, Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
[9] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[10] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[11] Seoul Natl Univ Hosp, Seoul, South Korea
[12] Janssen Res & Dev, Spring House, PA USA
[13] Janssen Res & Dev, Beerse, Belgium
[14] Janssen Res & Dev, Lexington, MA USA
[15] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4619
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Second or Third Line Therapy of unresectable or metastatic Urothelial Carcinoma Phase 3 Study of Erdafitinib versus Vinflunine or Docetaxel or Pembrolizumab in Patients with advanced Urothelial Carcinoma and Alterations in the FGFR Genes. (THOR) - AB 79/21 of the AUO
    Rexer, H.
    Peters, I.
    Retz, M.
    UROLOGIE, 2022, 61 (08): : 915 - 916
  • [32] Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).
    Siefker-Radtke, Arlene O.
    Necchi, Andrea
    Park, Se Hoon
    Garcia-Donas, Jesus
    Huddart, Robert A.
    Burgess, Earle F.
    Fleming, Mark T.
    Rezazadeh, Arash
    Mellado, Begona
    Varlamov, Sergei
    Joshi, Monika
    Duran, Ignacio
    Tagawa, Scott T.
    Zakharia, Yousef
    Qi Keqin
    Monga, Manish
    Sondhi, Manu
    OHagan, Anne
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [33] Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations
    Siefker-Radtke, A. O.
    Mellado, B.
    Decaestecker, K.
    Burke, J. M.
    O'Hagan, A.
    Avadhani, A.
    Zhong, B.
    Santiago-Walker, A.
    De Porre, P.
    Brookman-May, S.
    Garcia-Donas, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
    Pant, S.
    Arnold, D.
    Tabernero, J.
    Loriot, Y.
    Folprecht, G.
    Haag, G. M.
    Palmer, D.
    Prenen, H.
    Coward, J.
    Lugowska, I.
    Goeminne, J-C.
    Cervantes, A.
    Gutierrez, M.
    Sweiti, H.
    Hammond, C.
    Najmi, S.
    Thomas, S.
    Triantos, S.
    Crow, L.
    Schuler, M. H. H.
    ANNALS OF ONCOLOGY, 2023, 34 : S898 - S898
  • [35] Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).
    Soria, Jean-Charles
    Strickler, John H.
    Govindan, Ramaswamy
    Chai, Seungjean
    Chan, Nancy
    Quiroga-Garcia, Vanesa
    Bahleda, Rastislav
    Hierro, Cinta
    Zhong, Bob
    Gonzalez, Martha
    Santiago-Walker, Ademi E.
    Parekh, Trilok V.
    Luo, Feng Roger
    Sullivan-Chang, Loretta
    Xie, Hong
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
    Rose, Tracy L.
    Weir, William H.
    Mayhew, Gregory M.
    Shibata, Yoichiro
    Eulitt, Patrick
    Uronis, Joshua M.
    Zhou, Mi
    Nielsen, Matthew
    Smith, Angela B.
    Woods, Michael
    Hayward, Michele C.
    Salazar, Ashley H.
    Milowsky, Matthew I.
    Wobker, Sara E.
    McGinty, Katrina
    Millburn, Michael V.
    Eisner, Joel R.
    Kim, William Y.
    BRITISH JOURNAL OF CANCER, 2021, 125 (09) : 1251 - 1260
  • [37] Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
    Tracy L. Rose
    William H. Weir
    Gregory M. Mayhew
    Yoichiro Shibata
    Patrick Eulitt
    Joshua M. Uronis
    Mi Zhou
    Matthew Nielsen
    Angela B. Smith
    Michael Woods
    Michele C. Hayward
    Ashley H. Salazar
    Matthew I. Milowsky
    Sara E. Wobker
    Katrina McGinty
    Michael V. Millburn
    Joel R. Eisner
    William Y. Kim
    British Journal of Cancer, 2021, 125 : 1251 - 1260
  • [38] Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.
    Koshkin, Vadim S.
    Sonpavde, Guru P.
    Hwang, Clara
    Mellado, Begona
    Tomlinson, Gareth
    Shimura, Masashi
    Chisamore, Michael Jon
    Gil, Maciej
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [39] Erdafitinib in pediatric patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alterations: RAGNAR study pediatric cohort.
    Witt, Olaf
    Geoerger, Birgit
    Dirksen, Uta
    Sait, Sameer Farouk
    Reardon, David A.
    Shih, Kent C.
    Diez, Blanca D.
    Caran, Eliana Maria Monteiro
    Karakawa, Shuhei
    Stuyckens, Kim
    Liao, Huimin
    Najmi, Saltanat
    Hammond, Constance
    Santiago-Walker, Ademi E.
    Sweiti, Hussein
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer
    Wang, Li
    Gong, Yixuan
    Saci, Abdel
    Szabo, Peter M.
    Martini, Alberto
    Necchi, Andrea
    Siefker-Radtke, Arlene
    Pal, Sumanta
    Plimack, Elizabeth R.
    Sfakianos, John P.
    Bhardwaj, Nina
    Horowitz, Amir
    Farkas, Adam M.
    Mulholland, David
    Fischer, Bruce S.
    Oh, William K.
    Sharma, Padmanee
    Zhu, Jun
    Galsky, Matthew D.
    EUROPEAN UROLOGY, 2019, 76 (05) : 599 - 603
12345